Stock Market Manager Weekly Update: April 5th, 2023

Weekly Update: April 5th, 2023

Black Swan Connection Newsletter Signup

Breaking News

Remember that old song American Pie.

Every day when I log into the news it’s “Bad news on the doorstep, I couldn’t take one more step”

For sure no step to putting cash into the market.

Gold nears all-time high, VC funding down 53% and it hasn’t bottomed yet.

U.S. stocks were mostly down, with tech stocks sinking more markedly, after another hiring report showed a slowdown in private-sector job growth and a separate print showed growth at U.S. service providers also experienced a pullback. Treasury yields moved down sharply. The yield on the 10-year note slid to 3.302%. The move came after a weak ADP payrolls report on private-sector job growth.

One could argue that past market cycle turns were marked by very negative investor sentiment, which is certainly where we are now and add that to increasing bond yields a flight to safety is almost foregone conclusion.

Check it out here

Corporate News

Sponsored by:

The 21st Century Investment Bank Capital Raises + Strategic Advisory

Donald Capital is a boutique Investment Bank that focuses on raising capital for emerging growth companies in the U.S. and around the globe.

Ideally, we like to work with Private and Public companies with a good management team, a compelling business plan, and the ability to gain market share.

For more information go to: www.DonaldCapital-NY.com

3-15-2023 Can B Corp. (OTC CANB)

Can B Corp. Completes Corporate Debt Restructuring to Position for Uplisting to National Securities Exchange

HICKSVILLE, NY, March 15, 2023 (GLOBE NEWSWIRE) — via NewMediaWire – Can B Corp. (OTCQB: CANB) (“Can B” or the “Company”), a health and wellness company specializing in developing, producing, and selling hemp-derived cannabinoid products and durable medical devices, is pleased to announce it has successfully completed a corporate debt restructuring.

Through the restructuring, Can B raised $1.55 million of new capital and extended previously due notes payable totaling $7.0 million to September 1, 2023, and December 31, 2024. Specifically, three Promissory Notes issued to three funds in early 2022 and three Promissory Notes issued to three private investors in late 2022 were restructured to extend maturity dates to late in 2023 to give the Company an additional window to deploy the capital from the new raise.

Read Complete Release

3-6-2023 International Food and Beverage (OTC IFBC)

See the latest investor package. Dino is really getting traction.

About Us

2-15-2023 Antibe Therapeutics, Inc. (OTCQX ATBPF)
Antibe Reports Q3 2023 Interim Financial and Operating Results

– Recent animal data on otenaproxesul’s new formulation confirm rapid drug uptake and potential for effective pain management
– Targeting first clinical dose in calendar Q3 2023; Phase II top-line data within 12 months
– Ended quarter with $42.4 million in cash and equivalents, providing over two years of runway

TORONTO, February 15, 2023–(BUSINESS WIRE)–Antibe Therapeutics Inc. (TSX: ATE, OTCQX: ATBPF), a clinical-stage company leveraging its hydrogen sulfide platform to develop next-generation safer therapies to target inflammation, has filed its financial and operating results for the fiscal quarter ended December 31, 2022.

Read Complete Release

1-31-2023 Coeptis Therapeutics, Inc. (OTC COEP)
Coeptis Therapeutics Enters into Sponsored Research Agreement with the University of Pittsburgh to Advance SNAP-CAR Development Program

Coeptis to collaborate with the University of Pittsburgh to expand pre-clinical development of SNAP-CAR T cells targeting HER2-positive cancers

WEXFORD, Pa., Jan. 31, 2023 /PRNewswire/ — Coeptis Therapeutics Holdings, Inc. (NASDAQ: COEP) (“Coeptis” or “the Company”), a biopharmaceutical company developing innovative cell therapy platforms for cancer, today announced a sponsored research agreement with the University of Pittsburgh to advance pre-clinical development of SNAP-CAR T cells targeting HER2 as well as identify opportunities to expand the applicability of SNAP-CAR in oncology. SNAP-CAR, which Coeptis licensed from the University of Pittsburgh, is a multi-antigen chimeric antigen receptor T cell (CAR T) technology that can be adapted to different cancer indications, including hematologic and solid tumors.

Read Complete Release

Alternative Investments

Check out our latest commercial properties including an Amazing Private Island or Resort Development Property in Panama

3700 Acre Private Island in the Las Perlas Islands

7.4 Acre beachfront paradise for development or private retreat

Message me on Linkedin and check our latest commercial listings:

https://www.linkedin.com/in/carldilley/

Please subscribe to our newsletter to get ongoing Real Estate and Alternative Investing updates:

Black Swan Connection Newsletter Signup

April 5, 2023
COMPANY QUOTES, LISTINGS RESEARCH AND NEWS
Coeptis Therapeutics, Inc. Ecrid, Inc (ECDD) Profile
Antibe Therapeutics, Inc (ATBPF) Profile 11/11/2018 News
Can B Corp (CANB) Profile News
Endurance Exploration Group, Ltd (EXPL) Profile 03-26/19 News
International Food and Beverage Profile

Bank Stocks and ETFs – Time to Buy?
April 4, 2023 by Paul Henneman

The Editor-in-Chief of well-respected publisher ETF Stream, Tom Eckett, published a rare editorial Friday March 24 saying the big selloff in banks due to fear of contagion was close to over. He said at these levels, bank ETFs were at rarely seen low levels compared with earnings expectations and should not be thrown off too much by the so-called crisis caused by half a dozen bad actors. He especially prefers ETFs to bank stocks in this situation because there is safety in numbers. So even if one more bad actor is found, the ETF won’t be hurt that much.